SAB BIOTHERAPEUTICS, INC. (SABS)

3.79 -3.56% (-0.14)

Over 1M: +6.2%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

3.6 3.8
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Operating Income: -12.7M Q3 '25 — Operating Cash Flow: -13M Q3 '25 — Net Income: 45.4M Q4 '25 — Operating Income: -15.8M Q4 '25 — Operating Cash Flow: -16.8M Q4 '25 — Net Income: -16.9M Q1 '26 — Operating Income: -20M Q1 '26 — Operating Cash Flow: -14.3M Q1 '26 — Net Income: -18.9M Q2 '26 — Operating Income: -23.4M Q2 '26 — Operating Cash Flow: -9.8M Q2 '26 — Net Income: -22.5M -15M 0 15M 30M 45M 60M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Income Operating Cash Flow Net Income

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.5
ROIC -49.2%
Accruals 17.3%
ROA -5.4%
ROCE -31.7%
ROE -5.9%
Asset turnover —
Capex / sales —
EBITDA margin —
FCF margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
SBC / sales —

1 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Interest cover -310.3×
Cash / Debt 32.1×
Debt / Eq 0.015×
Debt payback 0.0 yr
Quick ratio 9.2×
Cash runway 1.8 yr
F-score 3.9 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales CAGR 4Y -100.0%
Sales/sh Y/Y -100.0%
Sales Q/Q -62.4%
Shares change +563.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.